Efavirenz News and Research

RSS
Efavirenz, also known as EFV or Sustiva, is a type of medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Efavirenz was approved by the FDA on September 17, 1998, for use with other antiretroviral agents in the treatment of HIV infection in adults and children ages 3 and older. This medicine does not cure HIV infection or AIDS and does not reduce the risk of passing the virus to other people. Efavirenz may also be used with other antiretroviral medications to prevent HIV in people who have been exposed to the virus in the work place, such as health care providers who come in contact with HIV infected blood through an accidental needle stick.
States to explore putting restrictions on AIDS drug Trizivir

States to explore putting restrictions on AIDS drug Trizivir

FDA reinforces use of Sustiva in first-line HIV combination therapy

FDA reinforces use of Sustiva in first-line HIV combination therapy

Comparison of antiretroviral therapies shows that tenofovir DF and stavudine are equally effective

Comparison of antiretroviral therapies shows that tenofovir DF and stavudine are equally effective

Weekly cycles of once-daily anti-HIV drugs could reduce cost of HIV treatment

Weekly cycles of once-daily anti-HIV drugs could reduce cost of HIV treatment

Weekly cycles of once-daily anti-drugs could reduce cost of HIV treatment

Weekly cycles of once-daily anti-drugs could reduce cost of HIV treatment

Plans for once-daily, fixed-dose combination of three anti-HIV drugs

Plans for once-daily, fixed-dose combination of three anti-HIV drugs